NCT07520357

A Phase II Clinical Study of SHR-A1904 Monotherapy in Second-Line or Later Treatment of Advanced Neuroendocrine Carcinoma

A Phase II Clinical Study of SHR-A1904 in Second-Line or Later Treatment of Advanced Neuroendocrine Carcinoma

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 23 (estimated)
• Sponsor: Beijing GoBroad Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, single-center, phase II trial designed to evaluate the efficacy and safety of SHR-A1904 monotherapy in second-line or later treatment of advanced neuroendocrine carcinoma. The primary endpoint is the objective response rate. Secondary endpoints include progression free survival, overall survival rate, duration of response, disease control Rate and adverse event.

Conditions

• Advanced Neuroendocrine Carcinoma

Interventions

Type	Name	Description
DRUG	SHR-A1904 Injection	SHR-A1904

Timeline

• Start date: 2026-04-30
• Primary completion: 2028-02-28
• Completion: 2029-02-28
• First posted: 2026-04-09
• Last updated: 2026-04-09

Locations

1 site across 1 country: China